SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Diagnocure CUR
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Cal Gary who wrote (123)6/18/2001 11:34:02 AM
From: Mr. L. Neufeldt  Read Replies (1) of 132
 
This part of the news release is important:

"toward the product
development and automation of the uPM3 diagnostic test for prostate cancer;
and
continuing discussions with several potential partners for the
commercialization of the uPM3 test. Starting at the end of this month,
DiagnoCure will be conducting preliminary clinical trials on 200 patients,
from which results should be available by September."

The major failing of ImmunoCyt is that it is not as automated as other tests. It's an excellent test...they just need to make it more user friendly.
To that goal uPM3 has been delayed. They're trying to make this test more user friendly.
Preliminary clinical trials of the test prior to FDA submittal, I believe, is a good thing. If the results are positive it should solidify the value or increase the value when looking for a partner in it's submittal to FDA and subsequent marketing.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News